Myeloproliferative neoplasms: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• ABL1 0
• JAK 25
• TP53 1
• PDGFR 0
• STAT3 0
• PI3K 0
• ERK 1
• FGFR 1
• FLT3 3
• mTOR 0
• AKT 0
• BCL-2 2
• IDH 3
• JNK 0
• HIF-1 0
• CSF1R 3
• HSP90 0
• MAPK 0
• MEK 2
• AMPK 0
• CD123 0
• CD19 0
• CD38 0
• IL-6 0
• KMT2A 0
• MDM2 0
• MYC 0
• NRF2 0
• PPAR 0
• RAS 0
• RUNX1 0
• ATM 0
• CD33 1
• CD40 0
• CDK4/6 1
• CXCR4 0
• EZH2 0
• G6PD 0
• HDAC 0
• KRAS 0
• NF1 0
• NLRP3 0
• NOTCH1 0
• NPM1 0
• NTRK 0
• PD-1 0
• PD-L1 0
• SGLT2 0
• SIRT1 0
• YAP 0

19 of 19+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-GF

  Identification of novel genetic regulators governing leukaemic transformation from myeloid proliferative neoplasms (MPN2AML)

  Medizinische Hochschule Hannover· Hannover, Germany· EU contribution €313,395· until Aug 2029· 2 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Role of CD24 and CD24hi Neutrophils in key co-morbidities associated with the MyeloProliferative Neoplasms (NeutroMPN)

  Universidad de Sevilla· Sevilla, Spain· EU contribution €209,915· until May 2028· 2 countries

• European Commission (Horizon Europe) · HORIZON-ERC

  Deciphering fibrosis reversal mechanisms in chronic blood cancer for identification of novel predictive and therapeutic strategies (Rewind-MF)

  Universitaetsklinikum Aachen· Aachen, Germany· EU contribution €1,999,313· until Mar 2029

3 of 3 running projects, newest first. Listed amounts together: €2.5m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)

  NCT04551066· Incyte Corporation· Updated 21 Oct 2025

  “The study was terminated due to futility.”Registry text, quoted unchanged. Source

• Terminated

  To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)

  NCT04551053· Incyte Corporation· Updated 2 Oct 2025

  “The study was terminated due to futility.”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)

  NCT04551066· Incyte Corporation· Source

• To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)

  NCT04551053· Incyte Corporation· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 8
• Organoids 1
• Mendelian Randomization Analysis 1
• CRISPR-Cas Systems 2
• Gene Expression Profiling 14
• Sequence Analysis, RNA 2
• Whole Genome Sequencing 2
• Exome Sequencing 4
• Proteomics 7
• Metabolomics 3
• Mass Spectrometry 2
• Flow Cytometry 19
• Immunohistochemistry 2
• Liquid Biopsy 1
• Xenograft Model Antitumor Assays 22
• Magnetic Resonance Imaging 14
• Machine Learning 7
• Deep Learning 3
• Cohort Studies 16
• Genome-Wide Association Study 1

• Longitudinal Single-Cell RNA Sequencing Reveals Evolution of Microstates and Macrostates in Chronic Myeloid Leukemia.

  Cancer Res, Nov 2026

• scDRP: disentangled representation learning for predicting single-cell responses to perturbations and estimating individual treatment effects.

  Brief Bioinform, Sept 2026

• Single-cell long-read genotyping of transcripts reveals discrete mechanisms of clonal evolution in post-MPN AML.

  Blood Adv, Jul 2026

• Clonal Metamorphosis: Deconstructing MPN Evolution with Single-Cell and Spatial Multi-Omics.

  Clin Exp Med, Jun 2026

• High-dimensional spatiotemporal single-cell atlas and 3D imaging of the bone marrow microenvironment during CML progression.

  Blood, May 2026

• Single cell transcriptional evolution of myeloid leukemia of Down syndrome.

  Nat Commun, Apr 2026

• Understanding drug resistance in chronic myeloid leukemia through the lens of leukemic stem cell states: insights from single-cell analyses.

  Haematologica, Apr 2026

• Sabotaged Integral HSC Heterogeneity Underlies Essential Thrombocythemia Development.

  Adv Sci (Weinh), Nov 2025

See which targets of this disease your abstract mentions, and go to the people working on them.